Still, it would be of interest to determine the precise expansion of high vs. low avidity tumor-responding CD8 T-cells over time during vaccination at the clonotype level, but this would require the development of combined single cell TCR-pMHC affinity and sequencing technologies, currently not available. This evidence concerns the gene CD8A and neoplasm.